Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI351 + cetuximab
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
IBI351 + cetuximab is a combination therapy investigated primarily for solid tumors harboring the KRAS G12C mutation, particularly in colorectal cancer and potentially other cancers. **IBI351 (fulzerasib, GFH925)** is an orally administered, selective, covalent, and irreversible inhibitor of KRAS G12C, designed to block the activation of the KRAS G12C pathway by modifying the mutant cysteine residue, thereby inhibiting downstream signaling that drives cancer cell proliferation and survival. **Cetuximab** is a chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR), inhibiting receptor activation and downstream oncogenic signaling. This combination is being studied to overcome resistance mechanisms and enhance anti-tumor efficacy in KRAS G12C-mutant cancers. Preliminary phase 2 results in metastatic colorectal cancer show an objective response rate of 80% and a disease control rate of 100% among evaluable patients, including good activity in those with brain metastases.
- Brand names
- fulzerasib
- Other names
- IBI351 (GFH925) + cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on IBI351 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI351 + cetuximab.